Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients With EGFR Wild-Type Non-Small-Cell Lung Cancer: The Never-Ending Story

被引：13
|
作者：
Gelsomino, Francesco [1 ]
Agustoni, Francesco [1 ]
Niger, Monica [1 ]
Valota, Marika [1 ]
Haspinger, Eva R. [1 ]
机构：
[1] Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, I-20133 Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 26期
关键词：
PHASE-III TRIAL; PLATINUM-BASED CHEMOTHERAPY; DOUBLE-BLIND; OPEN-LABEL; MAINTENANCE THERAPY; 1ST-LINE ERLOTINIB; 2ND-LINE TREATMENT; GEFITINIB; MULTICENTER; PLACEBO;
D O I：
10.1200/JCO.2013.50.2617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3291 / 3293
页数：3
相关论文
共 50 条
  • [21] Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
    Choi, Yong Won
    Choi, Jin-Hyuk
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (03): : 422 - 428
  • [22] Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
    Woo, Hyun Sun
    Ahn, Hee Kyung
    Lee, Ha Yeon
    Park, Inkeun
    Kim, Young Saing
    Hong, Junshik
    Sym, Sun Jin
    Park, Jinny
    Lee, Jae Hoon
    Shin, Dong Bok
    Cho, Eun Kyung
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1311 - 1315
  • [23] Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
    Hyun Sun Woo
    Hee Kyung Ahn
    Ha Yeon Lee
    Inkeun Park
    Young Saing Kim
    Junshik Hong
    Sun Jin Sym
    Jinny Park
    Jae Hoon Lee
    Dong Bok Shin
    Eun Kyung Cho
    Investigational New Drugs, 2014, 32 : 1311 - 1315
  • [24] Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR -Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    Nishino, Mizuki
    Lu, Junwei
    Hino, Takuya
    Vokes, Natalie, I
    Janne, Pasi A.
    Hatabu, Hiroto
    Johnson, Bruce E.
    JCO PRECISION ONCOLOGY, 2021, 5 : 1603 - 1610
  • [25] Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
    Chen, Yuh-Min
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2013, 76 (05) : 249 - 257
  • [26] Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma
    Prabhu, V. Vinod
    Devaraj, S. Niranjali
    JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, 2017, 36 (02) : 151 - 158
  • [27] Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
    Raimbourg, Judith
    Joalland, Marie-Pierre
    Cabart, Mathilde
    de Plater, Ludmilla
    Bouquet, Fanny
    Savina, Ariel
    Decaudin, Didier
    Bennouna, Jaafar
    Vallette, Francois M.
    Lalier, Lisenn
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (08) : 1634 - 1644
  • [28] Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer
    De Luca, A.
    Normanno, N.
    CURRENT DRUG TARGETS, 2010, 11 (07) : 851 - 864
  • [29] Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues
    K. Bencardino
    M. Manzoni
    S. Delfanti
    A. Riccardi
    M. Danova
    G. R. Corazza
    Internal and Emergency Medicine, 2007, 2 : 3 - 12
  • [30] Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations?
    Haspinger, Eva R.
    Garassino, Marina Chiara
    Torri, Valter
    Cinquini, Michela
    De Braud, Filippo
    Gelsomino, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) : 859 - 863
12345